trastuzumab deruxtecan: a promising agent for treating her2-low breast cancer?
Published 3 years ago • 1.4K plays • Length 4:01Download video MP4
Download video MP3
Similar videos
-
6:51
adcs for her2 and her2-low breast cancer
-
2:21
adcs for the treatment of her2-low breast cancer
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
2:01
destiny-breast04: practice-changing results for her2-low breast cancer
-
1:29
tuxedo-1: trastuzumab deruxtecan for the treatment of her2-positive breast cancer brain metastases
-
1:24
novel treatment options for her2-low breast cancer
-
1:16
her2-low expression in breast cancer
-
1:36
is her2-low a distinct subtype of breast cancer?
-
1:09
the exciting new field of her2-low breast cancer
-
0:31
remaining questions regarding her2-low breast cancer
-
2:12
trastuzumab deruxtecan in her2-low advanced breast cancer | nejm
-
2:05
latest news in her2-low breast cancer
-
0:56
destiny-breast04: t-dxd for patients with her2-low mbc
-
2:15
treatment strategies for her2 metastatic breast cancer
-
0:59
the significance of her2 expression for the activity of trastuzumab deruxtecan
-
2:37
remarkable data: trastuzumab deruxtecan for her2 bc
-
5:59
trastuzumab deruxtecan for the treatment of her2 breast cancer
-
4:15
debbrah: t-dxd in her2 or her2-low advanced breast cancer with cns involvement
-
1:35
advances in novel adcs for her2-expressing breast cancer